Pimecrolimus 1% cream for anogenital lichen sclerosus in childhoodReport as inadecuate




Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood - Download this document for free, or read online. Document in PDF available to download.

BMC Dermatology

, 4:14

First Online: 14 October 2004Received: 03 May 2004Accepted: 14 October 2004

Abstract

BackgroundLichen sclerosus is a chronic inflammatory disease with a predilection of the anogenital region. Because of the potential side effects of repeated local application of potent glucocorticosteroids, equally-effective, safer therapeutic options are required, especially in the treatment of children.

Case presentationsWe report on the efficacy of twice-daily application of pimecrolimus 1% cream in four prepubertal girls range of age: 4 to 9 years who suffered from anogenital lichen sclerosus. After three to four-month treatment, all patients had almost complete clinical remission including relief from itch, pain and inflammation. Only minor improvement was observed for the white sclerotic lesions. No significant side effects have been observed.

ConclusionsTopical pimecrolimus appears to be an effective and safe treatment for children with anogenital lichen sclerosus. The clinical benefits observed in the four patient presented particularly include relief of pruritus, pain and inflammation. Vehicle-controlled studies on a larger number of patients are now warranted to substantiate our promising findings, and to investigate long-term efficacy and safety of topical pimecrolimus in anogenital lichen sclerosus.

List of abbreviationsLichen sclerosusLS

glucocorticosteroidsGCS

Electronic supplementary materialThe online version of this article doi:10.1186-1471-5945-4-14 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Stefanie Boms - Thilo Gambichler - Marcus Freitag - Peter Altmeyer - Alexander Kreuter

Source: https://link.springer.com/







Related documents